Fig. 3: Antitumor effects of anti-CD47 Ab-coated WT tumor or tumor TA-expressing cells.
From: Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice
a Titration of anti-CD47 antibody for blocking CD47 on tumor cells. B16F0 WT cells were incubated with 2-fold serially diluted rat anti-mouse CD47 mAb MIAP301 (blocking; rat IgG) at 4 °C for 1 h, then stained with AF647-conjugated anti-CD47 mAb MIAP301 (left) or with AF647-conjugated goat anti-rat IgG (right). The numbers in the left and right sides of each histogram denote the concentration of anti-CD47 blocking mAb and MFI of secondary staining with AF647-conjugated antibodies. b Survival of mice that received intrasplenic injection of PBS (n = 5), 20 μg/mL anti-CD47 Ab-coated WT OVA-Tg splenocytes (n = 7) or CD47KO OVA-Tg splenocytes (n = 8), followed 7 days later by injection (i.v.; 2.5 × 106) of EG7 cells. c Tumor growth in mice that were intrasplenically vaccinated with media (n = 5), or with irradiated WT B16F0 (n = 5), WT B16F0 coated with anti-CD47 antibody (20 μg/mL; n = 8), or CD47KO B16F0 (n = 7) cells, followed 7 days later by subcutaneous injection of 2 × 105 WT B16F0 melanoma cells. d Tumor growth in mice that were intrasplenically vaccinated with media (n = 8), or with irradiated WT B16F10 (n = 7) or anti-CD47 Ab-coated WT B16F10 (20 μg/mL; n = 7), followed 7 days later by subcutaneous injection of 1 × 105 WT B16F10 melanoma cells. e Tumor growth in mice that were subcutaneously vaccinated with media (n = 5) or with irradiated anti-CD47 Ab-coated WT B16F10 (20 μg/mL; n = 10), followed 7 days later by subcutaneous injection of 2 × 105 WT B16F10 melanoma cells. Tumor growth is shown as tumor volumes (mean ± SEM) over time. Source data are provided as a Source Data file.
